TICKERNOMICS Sign up
Last Update: 2024-12-27 15:24:05
Arcutis Biotherapeutics Inc. ( ARQT ) https://www.arcutis.com
14.93USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
ARQT
352.42%
SPY
32.66%
-28.70%
ARQT
SPY
108.59%
ARQT
0.00%
SPY
302.52%
ARQT
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1863.29
1738.14
1.47
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-9.53
13.43
11.90
-14.54
0.00
-11.12
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-87.29
87.70
-91.95
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-190.33
-45.27
0.00
Other Earnings and Cash Flow Stats:
Arcutis Biotherapeutics Inc. ( ARQT ) Net Income TTM ($MM) is -195.54
Arcutis Biotherapeutics Inc. ( ARQT ) Operating Income TTM ($MM) is -181.93
Arcutis Biotherapeutics Inc. ( ARQT ) Owners' Earnings Annual ($MM) is 0.00
Arcutis Biotherapeutics Inc. ( ARQT ) Current Price to Owners' Earnings ratio is 0.00
Arcutis Biotherapeutics Inc. ( ARQT ) EBITDA TTM ($MM) is -179.41
Arcutis Biotherapeutics Inc. ( ARQT ) EBITDA Margin is -91.95%
Capital Allocation:
Arcutis Biotherapeutics Inc. ( ARQT ) has paid 0.00 dividends per share and bought back -62.575039 million shares in the past 12 months
Arcutis Biotherapeutics Inc. ( ARQT ) has reduced its debt by 0.37699999999998 million USD in the last 12 months
Capital Structure:
Arcutis Biotherapeutics Inc. ( ARQT ) Interest-bearing Debt ($MM) as of last quarter is 205
Arcutis Biotherapeutics Inc. ( ARQT ) Annual Working Capital Investments ($MM) are 66
Arcutis Biotherapeutics Inc. ( ARQT ) Book Value ($MM) as of last quarter is 156
Arcutis Biotherapeutics Inc. ( ARQT ) Debt/Capital as of last quarter is 131%
Other Balance Sheet Stats:
Arcutis Biotherapeutics Inc. ( ARQT ) has 134 million in cash on hand as of last quarter
Arcutis Biotherapeutics Inc. ( ARQT ) has 172 million of liabilities due within 12 months, and long term debt 204 as of last quarter
Arcutis Biotherapeutics Inc. ( ARQT ) has 124 common shares outstanding as of last quarter
Arcutis Biotherapeutics Inc. ( ARQT ) has 0 million USD of preferred stock value
Academic Scores:
Arcutis Biotherapeutics Inc. ( ARQT ) Altman Z-Score is 0.30 as of last quarter
Arcutis Biotherapeutics Inc. ( ARQT ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Arcutis Biotherapeutics Inc. ( ARQT ) largest shareholder is owning shares at 0.00 ($MM) value
Watanabe Todd Franklin(an insider) Sold 15000 shares of Arcutis Biotherapeutics Inc. ( ARQT ) for the amount of $227566.50 on 2024-12-20
2.15% of Arcutis Biotherapeutics Inc. ( ARQT ) is held by insiders, and 111.85% is held by institutions
Arcutis Biotherapeutics Inc. ( ARQT ) went public on 2020-01-31
Other Arcutis Biotherapeutics Inc. ( ARQT ) financial metrics:
FCF:-167.81
Unlevered Free Cash Flow:-436.48
EPS:-1.34
Operating Margin:-87.29
Gross Profit Margin:87.70
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-106.07
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Arcutis Biotherapeutics Inc. ( ARQT ) :
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.